Decrescendo, NCT04675827: De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade |
|
|
| Suspended | 2 | 1065 | Europe, RoW | Pertuzumab and tratuzumab fixed dose combination, Adjuvant pertuzumab + trastuzumab FDC SC for 14 cycles, Fixed-dose combination of Perjeta and Herceptin for subcutaneous injection for 14 cycles, Trastuzumab emtansine, Adjuvant T-DM1 | Jules Bordet Institute, Breast International Group, Hoffmann-La Roche, International Drug Development Institute, Institut Curie | HER2-positive Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer, Node-negative Breast Cancer | 06/27 | 03/29 | | |
NCT04641676: A Study to Examine the Value of Broad Agnostic Next Generation Sequencing (NGS) Panel Testing Versus Reimbursed Organ-directed NGS: a Belgian Precision Study of the BSMO in Collaboration With the Cancer Center |
|
|
| Recruiting | N/A | 1000 | Europe | NGS testing | The Belgian Society of Medical Oncology, Foundation Medicine, Sciensano, Roche Pharma AG | Metastatic Cancer, Local Tumor Invasion | 09/22 | 12/22 | | |
BALLETT, NCT05058937: A Study to Examine the Clinical Value of Comprehensive Genomic Profiling Performed by Belgian NGS Laboratories: a Belgian Precision Study of the BSMO in Collaboration With the Cancer Centre |
|
|
| Recruiting | N/A | 936 | Europe | Comprehensive genomic profiling | The Belgian Society of Medical Oncology, Illumina, Inc., OncoDNA, PierianDx | Solid Tumor, Metastatic Cancer | 05/23 | 05/26 | | |
